The present invention provides an anti-human hemoglobin monoclonal antibody or an antibody kit for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample with ease, and an insoluble carrier particle to which the monoclonal antibody is immobilized, and a measurement reagent and a measurement method for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample using the same. The anti-human hemoglobin monoclonal antibody of the present invention does not react to free hemoglobin or free haptoglobin which is not formed in a complex, but specifically reacts to a hemoglobin-haptoglobin complex when the antibody is immobilized to an insoluble carrier particle and used.

Nanoparticles and microspheres are provided for delivering an anticancer agent or other active agents to a subject. The nanoparticles and the microspheres are formed from a core that is encased by a coating or shell that includes a somatostatin-albumin fusion protein or analogue thereof. The somatostatin-albumin fusion protein includes at least one albumin (or an analog thereof) moiety, at least one somatostatin moiety (e.g. SST-14, SST-28), and at least one spacer connecting albumin to albumin, somatostatin to somatostatin and/or albumin to somatostatin moieties.

The present invention relates to latex particles for measurement reagents, said latex particles having a coefficient of variation in particle diameters of 10% or less and an average particle diameter of 250 to 1000 nm. Each of the latex particles contains 20% by weight or more of a compound having a refractive index of 1.60 or more. The depth of a supernatant is 5 mm or less when a liquid dispersion having a solid matter concentration of 1% by weight, which is prepared by dispersing the latex particles in ultrapure water, is placed in a tubular 10-ml measuring cylinder having a body inner diameter of 10.8 mm and is then allowed to leave for 10 days. According to the particles, a measurement of a measurement sample can be performed at a high sensitivity even when the concentration of a substance to be tested in the measurement sample is low.

The present invention relates to latex particles for measurement reagents, said latex particles having a coefficient of variation in particle diameters of 10% or less and an average particle diameter of 250 to 1000 nm. Each of the latex particles contains 20% by weight or more of a compound having a refractive index of 1.60 or more. The depth of a supernatant is 5 mm or less when a liquid dispersion having a solid matter concentration of 1% by weight, which is prepared by dispersing the latex particles in ultrapure water, is placed in a tubular 10-ml measuring cylinder having a body inner diameter of 10.8 mm and is then allowed to leave for 10 days. According to the particles, a measurement of a measurement sample can be performed at a high sensitivity even when the concentration of a substance to be tested in the measurement sample is low.

A system and method are described that allow the autonomous collection of relevant data and samples from a patient during a clinical trial or during routine care. Sampling is accomplished by drawing multiple samples into tubing, such as microfluidic tubing, and using a pump to move the samples through the tubing. A spacer fluid is provided to separate each sample and to prevent contamination between each. A microcontroller is used to control the operation of the pump and to gather data about the patient from the electronic medical record or other alternative inputs, and the sampling, including data from onboard sensors.

A system and method are described that allow the autonomous collection of relevant data and samples from a patient during a clinical trial or during routine care. Sampling is accomplished by drawing multiple samples into tubing, such as microfluidic tubing, and using a pump to move the samples through the tubing. A spacer fluid is provided to separate each sample and to prevent contamination between each. A microcontroller is used to control the operation of the pump and to gather data about the patient from the electronic medical record or other alternative inputs, and the sampling, including data from onboard sensors.

An antibody for use in an immunoassay method, the antibody comprising an Fc region, wherein at least part of a glycan comprised in the Fc region has been removed.

An antibody for use in an immunoassay method, the antibody comprising an Fc region, wherein at least part of a glycan comprised in the Fc region has been removed.

The invention relates to a molecularly imprinted polymer, wherein the molecularly imprinted polymer comprises a functionalized polymer composition configured to molecularly bind a target molecule in a medium, wherein a chelating agent is molecularly bound to the functionalized polymer composition of the molecularly imprinted polymer, said chelating agent is releasable to the medium and is able to induce a change in the electrochemical properties of the medium once released from the molecularly imprinted polymer, and wherein the chelating agent is configured to be released to the medium from the molecularly imprinted polymer by molecular binding of the target molecule to the functionalized polymer composition of the molecularly imprinted polymer.

The invention relates to a molecularly imprinted polymer, wherein the molecularly imprinted polymer comprises a functionalized polymer composition configured to molecularly bind a target molecule in a medium, wherein a chelating agent is molecularly bound to the functionalized polymer composition of the molecularly imprinted polymer, said chelating agent is releasable to the medium and is able to induce a change in the electrochemical properties of the medium once released from the molecularly imprinted polymer, and wherein the chelating agent is configured to be released to the medium from the molecularly imprinted polymer by molecular binding of the target molecule to the functionalized polymer composition of the molecularly imprinted polymer.